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Abstract
Background: A major challenge facing us is the provision of health care and appropriate allocation
of available resources for the treatment of patients with breast cancer. This is of particular concern
in the provision of follow-up care. With the increasing incidence of breast cancer and the
improvements in survival which have resulted in up to 75% of patients surviving for more than five
years, an increasing resource is required. However, there is controversy as to the most appropriate
schedule for follow-up of these patients. This brief review has focused on the evidence-base and
guidelines that currently exist in the United Kingdom for the follow-up of patients who have been
treated for breast cancer.
Methods: A review of the current guidelines published in the United Kingdom for the follow-up
of patients with breast cancer (National Institute for Clinical Excellence, Scottish Intercollegiate
Guidelines Network, British Association of Surgical Oncology) and the randomised controlled
trials evaluating the follow-up of patients with breast cancer was undertaken.
Results: The results have demonstrated the different follow-up protocols currently indicated in
these guidelines within the same country. Furthermore, the lack of well designed, randomised
controlled trials on which to base a follow-up protocol for patients with breast cancer is apparent.
Conclusion: The evidence-base on which these guidelines have been developed is lacking. It is
apparent that well designed randomised controlled trials are needed urgently if we are to
understand the most appropriate and effective ways of following up patients with breast cancer.
Background
A major challenge in the provision of healthcare through-
out the world in the 21st century is trying to ensure that the
resources that are available meet the demand. Nowhere is
the situation more acute than in the provision of care for
patients with cancer. Whilst current statistics show that
one in three people in the world will develop a malignant
disease, this figure is the projected to increase dramatically
during the next 10 years.
Of particular concern has been the continual rise in the
incidence of breast cancer. Each year the incidence
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increases by approximately 2% and in the UK alone there
are 45,000 new cases per annum [1]. However, whilst the
incidence of breast cancer is increasing there have been
many improvements and developments in surgery, radio-
therapy, chemotherapy and hormone therapy for patients
with breast cancer [2]. The resultant improvements in sur-
vival are well recognised, and in Scotland, for example,
the five year survival has risen now to 75% [3]. These
improvements in survival are most welcome but we do
need to consider the utilisation and allocation of
resources for the follow-up of these patients and their con-
cerns as to their appropriate use.
Therefore, how should we follow-up patients with breast
cancer who have undergone apparently curative therapy?
Firstly, the natural history of the disease, i.e. the probabil-
ity of local and/or distant recurrence of disease and the
psychological morbidity must be considered in this
regard. Secondly, the short-term and longer-term effects
on the patient of the various treatments that they have
been given (surgery, radiotherapy, chemotherapy, hor-
mone therapy) must also be taken into account. For exam-
ple after surgery, wound complications, postoperative
pain, lymphoedema and disorders of body image occur.
After chemotherapy and hormone therapy, there is risk of
cardiac dysfunction, neurotoxicity, premature meno-
pause, osteoporosis, osteoporotic fractures and psychoso-
cial disturbances that must be taken into account.
Furthermore, the possibility of a new primary cancer in
the ipsilateral, or contralateral, breast is also important.
In terms of the disease itself, approximately 25% of
patients will develop a systemic recurrence and die within
five years. Importantly, 60% to 80% of all recurrences that
occur are found during the first 3 years after treatment of
the primary tumour in the breast [4,5]. Furthermore, in
approximately three quarters of patients who develop dis-
ease recurrence, there are symptoms experienced by the
patient or there are abnormalities on clinical examination
to indicate recurrence of disease [4]. The risk of local dis-
ease recurrence in a breast which has been treated by
breast conservation surgery, or the risk of a second pri-
mary breast cancer occurring in either breast, is approxi-
mately 0.5% to 1% per annum, every year, following
completion of treatment [5].
Given this information, follow-up care for patients with
breast cancer has been directed primarily towards detect-
ing local and lymph node recurrence of disease and also
with the aim of detecting metastatic disease using clinical
examination and radiological and laboratory tests. How-
ever, three key questions should be considered when
planning a follow-up programme for patients with breast
cancer:
• How effective are regular hospital visits, clinical exami-
nation and laboratory investigations in detecting disease
recurrence, and how effective is mammography in identi-
fying local recurrence or second primary cancers in the
breast?
• If disease recurrence (local, regional systemic) is identi-
fied can the patients' outcome in terms of survival be
altered?
• If there is an effect on patients' outcome and survival,
then what is the optimal schedule of investigations in
order to achieve this?
What is the evidence?
A major limitation in trying to answer these questions is
the quality of the evidence that is available. Whilst there
are many retrospective and prospective observational
studies of follow-up of breast cancer patients, these are all
open to a variety of biases, which severely limit the inter-
pretation of these observations. The only way in which we
can answer the questions about follow-up is through well
designed, adequately powered and well conducted clini-
cal trials. At present there are few randomised controlled
trials in the follow-up of patients with breast cancer that
are available.
Table 1: Randomised trial of intensive schedule versus standard schedule of follow-up of patients in the "GIVIO" trial
Intensive follow-up (n = 655) Standard follow-up (n = 665)
• Physical examination every 3 months for 2 years; then 6monthly for 3 
years
• Physical examination every 3 months for 2 years; then 6monthly for 3 
years
• Serum biochemistry at each clinical examination • Mammography annually
• Chest x-ray every 6 months
• Isotope bone scan annually
• Liver ultrasound annually
• Mammography annually
(study detailed in JAMA 1994; 271: 1587–1592)World Journal of Surgical Oncology 2005, 3:54 http://www.wjso.com/content/3/1/54
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However, firstly can we affect the outcome of patients by
detecting recurrent disease at an early stage by using an
intensive follow-up schedule? In order to answer this
question, two trials have examined more than 2,500
patients who were randomised to a follow-up schedule of
clinical examination plus mammography or to a more
intensive follow-up schedule of laboratory tests combined
with radiological imaging. The protocols for these are
shown in Tables 1 and 2[6-8].
When the results of these trials were pooled together and
examined there was found to be no significant difference
in the five-year disease-free survival or overall survival for
either group of patients [9]. However, there was a differ-
ence in the detection of asymptomatic metastatic disease.
In patients followed-up intensively 31% had asympto-
matic metastases compared with only 21% in those being
less intensively followed-up. Therefore, although an
intensive follow-up schedule will detect metastatic disease
earlier it does not impact on the patients' outcome with
respect to disease-free and overall survival. In terms of
quality of life, there were no differences between the
patients in having intensive or less intensive follow-up
schedules.
Furthermore, a recent systematic review and meta-analysis
has focused on whether routine hospital visits were even
effective in detecting loco-regional recurrences in patients
who were asymptomatic following treatment for early
breast cancer [10]. A total of 5,045 patients from 12 stud-
ies were analysed. It was found that in asymptomatic
patients, only 40% of isolated loco-regional recurrences
were diagnosed by routine visits and tests [10] but the dif-
ficulties with interpretation of the studies due to their
poor quality was also clear from this analysis. However,
the majority of recurrences were identified outside the
patients planned routine follow-up schedule.
Another question that is now being asked, particularly in
view of the lack of oncologists in many areas in the world,
is what is the value of patients attending a "specialist" fol-
low-up clinic? In a trial designed to address this question,
after treatment for breast cancer 296 patients were ran-
domised to follow-up, either by their general practitioner
or by hospital specialist [11]. Although this was a small
study, it was stated that there was no significant difference
in the detection of metastases in the two groups of
patients. However, there was a 60% increased detection in
the group of patients being followed-up by the hospital
specialists, although this was dismissed because it did not
achieve statistical significance. Another important aspect
of the findings from this study was that there was no dif-
ference in the patients' quality of life. Furthermore,
patients in the general practitioner group were more satis-
fied with the continuity of care than patients' follow-up by
hospital specialists. The limitations of this study, particu-
larly in respect of the statistical power and short period of
follow-up do limit the conclusions that can be drawn. Fur-
thermore, one third of eligible patients declined to partic-
ipate in this study. A further well designed and larger
clinical study is necessary to address this issue.
An alternative approach to the follow-up was evaluated in
a Swedish multicentre study where the role of nurse-led
follow-up was examined [12]. A small group of 264
patients with early breast cancer were randomised to rou-
tine physician follow-up or follow-up by a nurse special-
ist. There was no difference in terms of patient
satisfaction, anxiety, or depression and there were no dif-
ferences between time to recurrence or death between the
two groups of patients. The authors did note that the
study was small and not powered to detect differences in
recurrence and survival. On the basis of these encouraging
results further studies would be required to confirm that
this is an alternative way of follow-up for certain selected
patients which may offer advantages in terms of continu-
ity of care, patient education and allow a more appropri-
ate utilisation of physician-time [12].
A key consideration is what do the patients themselves
want? One small, randomised trial of 211 patients has
addressed this issue [13]. Patients were randomised to
have either a conventional follow-up clinic visit schedule
(every 3 months for the first year, four months for the sec-
ond year, six months up until 5 years after initial diagnosis
and annually thereafter) or just to have mammography at
Table 2: Schedule for follow-up in the roselli del turco trial of intensive follow up
Intensive follow-up (n = 622) Standard follow-up (n = 621)
• Physical examination every 3 months for 2 years; then 6monthly for 3 
years
• Physical examination every 3 months for 2 years; then 6monthly for 3 
years
• Chest x-ray every 6 months • Mammography annually
• Isotope bone scan every 6 months
• Mammography annually
(JAMA 1999; 281; 1586 and JAMA 1994; 271: 1593–1597)World Journal of Surgical Oncology 2005, 3:54 http://www.wjso.com/content/3/1/54
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routine intervals (initially every year for 5 years, then two
yearly). Those patients who had undergone a mastectomy
had a slightly different mammographic schedule with a
mammogram one year after diagnosis and then every two
years subsequently [13].
The results of this study revealed that approximately twice
as many patients felt they would rather have a reduced
schedule of follow-up rather than a more intensive one.
Also the patients in the groups randomised to just mam-
mographic follow-up were satisfied with this. However, a
very important point to emerge was that this was not a
universal finding amongst all the patients in the study.
Importantly, those patients who were less than 50 years of
age, who were at a stage between two and five years after
diagnosis and those who had aggressive disease, were less
likely to participate in this study [13].
Just how do we follow-up patients and what are the 
guidelines?
Given the data from this small number of randomised tri-
als is it possible to decide upon, in an evidence-based
fashion, the most appropriate follow-up for patients with
breast cancer? The key facts to consider in attempting to
do this and which have emerged from these randomised
controlled trials are:
• 25% of patients develop recurrence and in 60% to 80%
of them this will be in the three years following initial
diagnosis,
• Hospital outpatient visits may detect 40% of locore-
gional recurrences in asymptomatic patients,
• A very intense schedule of hospital visits, laboratory and
imaging tests does not affect disease-free or overall sur-
vival compared with a less intense schedule of clinical
examination and mammography,
• Follow-up in hospital clinics compared with general
practice follow-up does show a trend towards an
increased detection of metastatic disease but quality of life
was no different although the longer term effects on sur-
vival are unclear
• Patients' preference is for less intense follow-up with the
exception of younger patients, those with more aggressive
disease and those who are at a stage of between two to five
years from their initial diagnosis.
With these considerations in mind, clinical practice guide-
lines which have been developed and defined as "system-
atically developed statements to assist practitioner and
patient decisions about appropriate health care for spe-
cific clinical circumstances" [14], have been developed for
the follow-up of patients with breast cancer. These guide-
lines have been developed on the basis of systematic
reviews of the literature and in each guideline there is usu-
ally an explanation of the classification of levels of evi-
dence (e.g. from meta-analyses, systematic reviews of
RCTs, case-control studies, cohort studies, non-analytic
studies and expert opinion), classification of grades of rec-
ommendation (e.g. based on the results from meta-analy-
ses of RCT, or from a high quality RCTs, or from case
control or cohort studies, or based on non-analytical stud-
ies or expert opinion) and also the guideline will state the
time when it is due to be updated.
In recent years in the United Kingdom, a number of differ-
ent guidelines have been produced in an attempt to
ensure that patients with breast cancer have the most
appropriate follow up. For example, the Association of
Breast Surgery at the British Association of Surgical Oncol-
ogy (BASO), the Scottish Intercollegiate Guidelines Net-
work (SIGN), and the National Institute of Clinical
Excellence, the Royal College of Radiologists and the Clin-
ical Outcomes Group of the Department of Health have
all tried to provide guidance as to the most appropriate
way of follow-up [15-19]. The key points to emerge from
these guidelines are shown in Table 3, and have their basis
in the data outlined above. In addition to these guidelines
from the UK, a variety of other organisations throughout
the world have also produced their own guidelines, which
consider follow-up of patients with breast cancer. It is
beyond the scope of this article to consider these in detail
but can be accessed elsewhere [20]. However, most rec-
ommend clinical examination every 3 to 6 monthly for 3
to 5 years, and then followed by annual clinical examina-
tions. As regards mammography, the trials addressing this
seems to recommend mammography six months after
completion of radiotherapy and then at 1 or 2 yearly inter-
vals thereafter.
It is always difficult for clinicians, particularly when sev-
eral different guidelines exist in one county. However, it is
easier to consider the areas common to these guidelines
initially. All the guidelines agree that follow-up should be
limited to clinical examination and mammographic sur-
veillance with their being no recommendations for other
laboratory or radiological imaging tests. But what is the
interval as which these should be carried out and for how
long? The difficulty is, of course, that there is no evidence
on which to make these recommendations.
However, perhaps a clinical examination every six months
for five years would be a reasonable recommendation but
with the caveat of the lack of information available. Even
more difficult to base on scientific evidence is the optimal
interval for mammographic surveillance. Again we do not
have the evidence but we must consider the randomisedWorld Journal of Surgical Oncology 2005, 3:54 http://www.wjso.com/content/3/1/54
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trials, what we understand about the biology of breast
cancer and recurrence, and what we know from the
various breast screening programmes that have been
implemented internationally. Given this data an annual
mammogram for five years and then every two years after
breast conserving surgery seems a reasonable compro-
mise. In patients who have had a mastectomy, then a sur-
veillance mammogram every two years also seems to be a
reasonable compromise for follow-up in these patients.
However, we emphasise the lack of evidence for recom-
mendations regarding mammographic surveillance.
This still leaves two important questions as to how long
the patients should be followed-up for and by whom?
Firstly, in terms of duration of follow-up, although we do
not have the evidence, the National Institute of Clinical
Excellence (NICE) recommends a limited period of fol-
low-up of 2 to 3 years unless patients are entered into clin-
ical trials. NICE also documents the financial savings that
would accrue if such a policy were adopted [17]. However,
there are many unanswered questions as to the appropri-
ateness of this that needs to be answered. As regards who
should follow-up the patient, one trial indicated that in
selected patients this could be the general practitioner, but
it is worth noting important exceptions as discussed
above. Furthermore, the longer-term consequences of this
approach remain unclear.
Another complicating factor with regard to follow-up is
that several recently published trials have had a major
impact on the usage of adjuvant hormone therapy, eg the
indication that the armomatase inhibitors may be supe-
rior to tamoxifen, the value of further treatment with
letrozole after 5 years of tamoxifen and the impact of
changing patients after two or three years tamoxifen treat-
ment to an aromatase inhibitor. Therefore, at the present
time we are still not sure what the optimum for adjuvant
hormonal therapy is and we also need to consider what
should happen to the patients who are currently taking
tamoxifen.
We also need to consider what will be the impact on bone
mass with the increasing use of aromatase inhibitors and
whether or not 'prophylactic' bisphosphonates may be
required. Furthermore, intensive folow up does increase
the rate of detection of asymptomatic metastases and
whilst this did not impact on patients survival in the stud-
ies from the 20 years ago, with the current advances in sys-
temic treatment (eg aromatase inhibitors, taxanes,
trastuzumad etc) is it not possible that early treatment
may now have survival advantages for these patients? One
must not under estimate the need for continuing audit of
results following the treatment for breast cancer and of the
morbidity in these patients undergoing 'multi-modality
therapy' which can have significant short and long term
consequences. These are just some of the issues to be con-
Table 3: Guidelines issued in the united kingdom for the follow-up of patients with breast cancer
Organisation Recommendation
The Association of Breast Surgery at the British Association of Surgical 
Oncology
• Patients on active treatment may be followed up until such treatment 
has been completed
• High risk patients may be followed up more closely with joint care by 
surgeons and oncologists according to local protocols
• Data about long term follow-up is essential in monitoring clinical 
outcomes
• Patients to be followed up for 5 years
• Routine mammography every 1 to 2 years for 10 years after diagnosis
Scottish Intercollegiate Guidelines Network (SIGN) • These guidelines state that there is insufficient clinical evidence to 
determine the optimal interval of clinical examination. They suggest that 
a "pragmatic schedule" should be adopted, for example, every 6 months 
for 2 years and then annually thereafter.
• For mammographic follow-up, in a breast which has been conserved, 
then this should be performed at least every 2 years and at intervals of 
not less than 1 year. For the contralateral breast mammography should 
be carried out every 1 – 2 years.
National Institute for Clinical Excellence (NICE) • Guidelines state that there should be a "limited" follow-up for 2 – 3 
years and should be agreed by "local networks". This would not 
normally exceed 3 years unless patients were in clinical trials.
• The guidelines state that local networks should agree evidence-based 
policy for the frequency of mammographic follow up
The Royal College of Radiologists • Guidelines recommend that mammography is carried out at least every 
2 years and not more than annually
The Clinical Outcomes Group, Department of Health • Recommends that mammography is carried out annually for 5 years 
and then every two years after thatWorld Journal of Surgical Oncology 2005, 3:54 http://www.wjso.com/content/3/1/54
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sidered when following-up patients following treatment
for breast cancer and therefore with increasing complexity
of management it is likely that specialist input will be nec-
essary still.
Conclusion
Despite the advances that have been made in the treat-
ment of patients with breast cancer we are still unclear as
to the optimal way in which patients should be follow-up
once treatment has been completed. Despite the publica-
tion of many different guidelines with recommendations
for follow-up it is clear that the evidence base on which
these are founded is lacking at the present time. Further-
more, the evidence is from trials that were commenced
twenty years ago and their relevance to the modern man-
agement of patients with breast cancer is now
questionable.
It is now important that we consider the research priori-
ties in follow-up of breast cancer patients, in particular
with respect to stratifying patients according to their risk
of disease recurrence, and the impacts of treatments on
physical and psychological morbidity and quality of life.
It is essential that well designed randomised controlled
trials are undertaken if we are to understand the most
appropriate and effective ways of following up patients
with breast cancer.
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